| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.25 | 2e-07 |
| mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0005 |
| mRNA | WZ-1-84 | GDSC1000 | pan-cancer | AAC | 0.18 | 0.0005 |
| mRNA | lapatinib | GDSC1000 | pan-cancer | AAC | 0.16 | 0.0008 |
| mRNA | LY-2157299 | CTRPv2 | pan-cancer | AAC | 0.23 | 0.001 |
| mRNA | neratinib | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | ML334 diastereomer | CTRPv2 | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | ibrutinib | CTRPv2 | pan-cancer | AAC | 0.13 | 0.003 |
| mRNA | Gemcitabine | gCSI | pan-cancer | AAC | -0.18 | 0.004 |
| mRNA | BRD-K51490254 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.004 |